DOCSLIB.ORG

Product Monograph

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Product Monograph Product Monograph Novel. Superior. Dual acting. Message from the Chairman’s Desk Dear Doctor, Greetings at a historic moment! We are indeed very pleased to announce the launch of our Novel, Superior, Dual Acting patented molecule LipaglynTM (Saroglitazar). This is the first drug ever to receive an approval for diabetic dyslipidemia - An Unmet Healthcare need. This is a landmark achievement not only for us, but for the entire healthcare fraternity in India. Discovered and developed by Zydus, Saroglitazar is a first-in-class molecule to be approved by the Drug Controller General of India to treat diabetic dyslipidemia or hypertriglyceridemia in type-2 diabetes not controlled by statins alone. Researched & developed over a span of 12 years, LipaglynTM is the first New Chemical Entity (NCE) from India to successfully complete the journey from the lab to the market. A team of over 400 dedicated research scientists at the Zydus Research Centre, Ahmedabad, guided the molecule through every stage, from the lab to the market. For patients with diabetic dyslipidemia, LipaglynTM is unique – • Superior safety profile - with a lower incidence of side events vs. current standard of care • Greater efficacy on lipid regulation (especially when taken in combination with statins) • Additionally, the drug also offers excellent glycemic control We are also embarking on a long term drug development program to globalize the molecule – in other emerging markets and in developed markets like Europe & USA. To familiarize you with our Novel, Superior & Dual Acting LipaglynTM, our medical team has compiled a product monograph specially for physicians like you. For further details you may visit www.lipaglyn.com Looking forward for your feedback on the therapeutic use of LipaglynTM. Warm Regards, Pankaj R. Patel Chairman and Managing Director Message from the Sr. VP’s Desk Dear Doctor, Greetings from Zydus Discovery!!! It is indeed a great pleasure to share this breakthrough of Zydus - LipaglynTM (Saroglitazar), India’s 1st NCE. This novel drug, discovered and developed through indigenous efforts, is approved for treating Diabetic Dyslipidemia – a global unmet healthcare need. This is a step forward in our commitment to serve the nation by strengthening the medical fraternity. The success of LipaglynTM can be a source of pride, not just for Zydus, but also for the Indian pharmaceutical industry and for the nation; encouraging more focus and investment on indigenous research. As you would know that today India is inching towards having the largest pool of diabetic patients globally. Moreover, nearly 80% of diabetic population have concomitant dyslipidemia and need a drug intervention for treatment. Our medical & R&D teams have compiled this product monograph with comprehensive information on Diabetic Dyslipidemia, current therapies and role of LipaglynTM in treatment of this condition. This monograph is comprised of three major sections– • Diabetic Dyslipidemia therapy area • LipaglynTM preclinical studies • LipaglynTM clinical studies Looking forward for your co-operation and guidance to enable LipaglynTM help every Diabetic Dyslipidemia patient in India lead a healthier life. Regards, M S Nath Sr. Vice President & Head SBU 2 (CVD) Preface Every fourth diabetic in the world is an Indian. As per an Indian Council of Medical Research (ICMR) study in 2011, the prevalence of diabetes has increased to 12-18% in urban India, 3-6% in rural India and another 14% having pre-diabetes. Translated into numbers, there were already 62.4 million diabetics and 77.2 million pre-diabetics in 2011 in India. The numbers are increasing exponentially. The reason is that the genetic susceptibility to develop diabetes is high in Indians. Indians have a low threshold for the risk factors like obesity, sedentary life habits and stress. These risk factors are applicable to all Indians irrespective of the place they live. Indians living in other countries too have a higher prevalence of diabetes compared to the natives and the Caucasian population. Diabetics have an increased cardiovascular risk. This risk gets exaggerated by lipid abnormalities additionally. Diabetics have an increased propensity to develop dyslipidemia (also known as ‘Atherogenic Diabetic Dyslipidemia’-ADD) characterized by high TG and/or low HDL-C and/ or small dense LDL-C. Indian type 2 diabetics are highly prone to be dyslipidemic, as a study found that 85.5% male, and, as high as 97.2% female Indian diabetics have dyslipidemia. Traditionally, diabetes and its accompanying dyslipidemia are managed by a variety of permutations and combinations of anti-diabetic and lipid-lowering drugs. The glycemic and lipid goals are not being met in the majority of patients because meeting these goals are a challenge. In the management of diabetes, insulin or the secretagogues cause hypoglycaemia, and the secretagogues can lead to exhaustion of the pancreatic beta cells. Metformin alone is not always sufficient, and the other insulin sensitizers like pioglitazone, acting by stimulating the nuclear peroxisome proliferator-activated receptors-γ (PPAR-γ) receptors, are under a cloud for their side effect profile. As far as lipids are concerned, statins at best are able to benefit 20-30% patients only. Fibrates, by stimulating the PPAR-α receptors, either alone or in combination with the statins, pose hazards of muscle toxicity. Niacin and fish-oils also do not meet the expectations. In such a scenario research got directed at developing dual PPAR-α/γ agonists which could address both the abnormalities of lipids and hyperglycemia in diabetic dyslipidemia. The potential of PPAR agonists to positively influence the cardiovascular disease risk in type 2 diabetics has remained an area of continuous medical interest. PPAR-α agonists (fenofibrate) and PPAR-γ agonist (pioglitazone) are approved respectively for lipid control and glycemic control in type 2 diabetes. However, increasing safety concerns with thiazolidinediones with regard to fluid retention, weight gain and congestive cardiac failure have resulted in new label warning for these agents. Hence, there was a strong need for a dual PPAR-α/γ agonist with beneficial effects in controlling both lipids and glycemic levels with all the necessary safety parameters. We bring to you the world’s first approved dual PPAR-α/γ agonist, LipaglynTM (saroglitazar), for your patients suffering from diabetic dyslipidemia, which has shown efficacy in improving both, the lipid as well as the glycemic parameters, with an excellent safety profile. Read the entire story of LipaglynTM in this monograph. Happy reading! Dr Anil J. Jaiswal VP – Medical Services Index Sr. No. Topic Page No. 1 Introduction: Burden of cardiovascular disease in India and its risk factors 11 2. Global and Indian diabetes prevalence 12 3. Diabetic dyslipidemia and its prevalence in India 13 4. Prevalence of hypertriglyceridemia in Indian diabetics 14 5. Classification of lipid parameters 15 6. Role of statins and fibrates in Atherogenic Diabetic Dyslipidemia 16 6.1 Statins 16 6.2 Fibric acid derivatives 16 7. Beyond LDL: The non-HDL-C guidelines 18 8. Triglycerides and CVD risk: Pathophysiology 20 9. Diabetic dyslipidemia, unmet needs and emerging role for dual PPAR-α/γ agonists 22 9.1 NCEP ATP III Guidelines 22 9.2 Emerging therapy approaches 24 10. Development of glitazars 26 10.1 What are PPARs? 26 10.2 Mechanism of action of PPAR agonists 26 10.3 Rationale for developing dual PPAR-α/γ agonists 26 10.4 History of development of dual PPAR-α/γ agonists 27 11. Introduction to LipaglynTM (Saroglitazar) 28 11.1 LipaglynTM – Physical and chemical properties 28 11.2 LipaglynTM - Formulation 29 12. LipaglynTM (Saroglitazar) - Pre-clinical studies 30 12.1 Preclinical safety and toxicity evaluation 32 12.2 Safety pharmacology 32 12.3 Effects on the cardiovascular system 33 12.4 Effects on the respiratory system 33 12.5 Supplemental and follow-up safety pharmacology studies 33 13. Clinical evidences of LipaglynTM (Saroglitazar) 35 13.1 Phase I studies 35 13.2 Phase II studies 36 13.3 Phase III studies 37 14. LipaglynTM (Saroglitazar) in the management of Atherogenic Diabetic Dyslipidemia 48 15. Prescribing information of LipaglynTM (Saroglitazar) 51 16. References 58 17. Abbreviations 61 1. Introduction: Burden of cardiovascular disease in India and its risk factors India accounts for 21% of the world’s global burden of disease. Non-communicable diseases (NCDs) are responsible for two-thirds of the total morbidity burden and about 53% of total deaths in India. This figure is expected to rise from 40.4% in 1990 to 59% by 2015. And, most importantly, two out of four leading NCDs in India are: Cardiovascular diseases (CVDs) Diabetes Mellitus (DM)1 India experienced the highest loss in potentially productive years of life worldwide. The leading cause of death was CVD; mostly affecting people aged 35-64 years. It has been calculated that, in 2000, 9.2 million years of productive life were lost in India.2 There are six leading risk factors associated with NCDs. They are: High blood glucose levels Altered lipid levels Physical inactivity Overweight/Obesity High blood pressure Tobacco use The prevalence of coronary heart disease (CHD) during 2003 in India was estimated to be 3-4% in rural areas (two-fold higher compared to 40 years ago), and 8-10% in urban areas (six-fold higher compared to 40 years ago), with a total affected population of 29.8 million (14.1 million in urban areas, and 15.7 million in rural areas). This estimate is comparable to the figure of 31.8 million affected, derived from extrapolations of the “Global Burden of Diseases Study”. These numbers likely underestimate the affected population as they do not account for those with silent myocardial infarction (MI) or otherwise asymptomatic CHD. In 1990, there were an estimated 1.17 million deaths from CHD in India, and the number was expected to almost double to 2.03 million by 2010.
Load more

Recommended publications
  • Rosiglitazone-Associated Fractures in Type 2 Diabetes an Analysis from a Diabetes Outcome Progression Trial (ADOPT)
    Clinical Care/Education/Nutrition/Psychosocial Research ORIGINAL ARTICLE Rosiglitazone-Associated Fractures in Type 2 Diabetes An analysis from A Diabetes Outcome Progression Trial (ADOPT) 1 7 STEVEN E. KAHN, MB, CHB DAHONG YU, PHD preclinical data and better understand the 2 7 BERNARD ZINMAN, MD MARK A. HEISE, PHD clinical implications of and possible interven- 3 7 JOHN M. LACHIN, SCD R. PAUL AFTRING, MD, PHD tions for these findings. 4 8 STEVEN M. HAFFNER, MD GIANCARLO VIBERTI, MD 5 WILLIAM H. HERMAN, MD FOR THE ADIABETES OUTCOME Diabetes Care 31:845–851, 2008 6 RURY R. HOLMAN, MD PROGRESSION TRIAL (ADOPT) STUDY 7 BARBARA G. KRAVITZ, MS GROUP* ype 2 diabetes is associated with an increased risk of fractures, with the risk increasing with longer duration OBJECTIVE — The purpose of this study was to examine possible factors associated with the T increased risk of fractures observed with rosiglitazone in A Diabetes Outcome Progression Trial of disease (1,2). These fractures affect pre- (ADOPT). dominantly the hip, arm, and foot (1–5) and occur despite the fact that bone min- RESEARCH DESIGN AND METHODS — Data from the 1,840 women and 2,511 men eral density is either normal or even in- randomly assigned in ADOPT to rosiglitazone, metformin, or glyburide for a median of 4.0 years creased in patients with type 2 diabetes were examined with respect to time to first fracture, rates of occurrence, and sites of fractures. compared with those who are not hyper- glycemic (5–7). Although the reason for RESULTS — In men, fracture rates did not differ between treatment groups.
    [Show full text]
  • The Antidiabetic Drug Lobeglitazone Has the Potential to Inhibit PTP1B T Activity ⁎ Ruth F
    Bioorganic Chemistry 100 (2020) 103927 Contents lists available at ScienceDirect Bioorganic Chemistry journal homepage: www.elsevier.com/locate/bioorg The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B T activity ⁎ Ruth F. Rochaa, Tiago Rodriguesc, Angela C.O. Menegattia,b, , Gonçalo J.L. Bernardesc,d, Hernán Terenzia a Centro de Biologia Molecular Estrutural, Departamento de Bioquímica, Universidade Federal de Santa Catarina, Campus Trindade, 88040-900 Florianópolis, SC, Brazil b Universidade Federal do Piauí, CPCE, 64900-000 Bom Jesus, PI, Brazil c Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisbon, Portugal d Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW Cambridge, UK ARTICLE INFO ABSTRACT Keywords: Protein tyrosine phosphatase 1B (PTP1B) is considered a potential therapeutic target for the treatment of type 2 Thiazolidinediones diabetes mellitus (T2DM), since this enzyme plays a significant role to down-regulate insulin and leptin sig- Lobeglitazone nalling and its over expression has been implicated in the development of insulin resistance, T2DM and obesity. PPAR-γ Some thiazolidinediones (TZD) derivatives have been reported as promising PTP1B inhibitors with anti hy- PTP1B perglycemic effects. Recently, lobeglitazone, a new TZD, was described as an antidiabetic drug that targetsthe Non-competitive inhibitors PPAR-γ (peroxisome γ proliferator-activated receptor) pathway, but no information on its effects on PTP1B have been reported to date. We investigated the effects of lobeglitazone on PTP1B activity in vitro. Surprisingly, lobeglitazone led to moderate inhibition on PTP1B (IC50 42.8 ± 3.8 µM) activity and to a non-competitive reversible mechanism of action.
    [Show full text]
  • Diabetes Mellitus: Patterns of Pharmaceutical Use in Manitoba
    Diabetes Mellitus: Patterns of Pharmaceutical Use in Manitoba by Kim¡ T. G. Guilbert A Thesis submitted to The Faculty of Graduate Studies in Partial Fulfillment of the Requirements for the Degree of MASTER OF SCIENCE Faculty of Pharmacy The University of Manitoba Winnipeg, Manitoba @ Kimi T.G. Guilbert, March 2005 TIIE UMYERSITY OF MANITOBA F'ACULTY OF GRADUATE STTJDIES +g+ù+ COPYRIGIIT PERMISSION PAGE Diabetes Mellitus: Patterns of Pharmaceutical Use in Manitoba BY Kimi T.G. Guilbert A ThesisÆracticum submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfillment of the requirements of the degree of MASTER OF SCIENCE KIMI T.G. GTIILBERT O2()O5 Permission has been granted to the Library of The University of Manitoba to lend or sell copies of this thesis/practicum, to the National Library of Canada to microfïlm this thesis and to lend or sell copies of the film, and to University Microfilm Inc. to publish an abstract of this thesis/practicum. The author reserves other publication rights, and neither this thesis/practicum nor extensive extracts from it may be printed or otherwise reproduced without the author's written permission. Acknowledgements Upon initiation of this project I had a clear objective in mind--to learn more. As with many endeavors in life that are worthwhile, the path I have followed has brought me many places I did not anticipate at the beginning of my journey. ln reaching the end, it is without a doubt that I did learn more, and the knowledge I have been able to take with me includes a wider spectrum than the topic of population health and medication utilization.
    [Show full text]
  • Identification of a Novel Selective Agonist of Pparc with No Promotion
    OPEN Identification of a novel selective agonist c SUBJECT AREAS: of PPAR with no promotion of DRUG DISCOVERY ENDOCRINE SYSTEM AND adipogenesis and less inhibition of METABOLIC DISEASES osteoblastogenesis Received 28 October 2014 Chang Liu, Tingting Feng, Ningyu Zhu, Peng Liu, Xiaowan Han, Minghua Chen, Xiao Wang, Ni Li, Yongzhen Li, Yanni Xu & Shuyi Si Accepted 5 March 2015 Published Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, China. 1 April 2015 Nuclear receptor peroxisome proliferator-activated receptor c (PPARc) plays an important role in the regulation of glucose homeostasis and lipid metabolism. However, current PPARc-targeting drugs such as Correspondence and thiazolidinediones (TZDs) are associated with undesirable side effects. We identified a small molecular requests for materials compound, F12016, as a selective PPARc agonist by virtual screening, which showed moderate PPARc should be addressed to agonistic activity and binding ability for PPARc. F12016 did not activate other PPAR subtypes at 30 mM and S.S. (sisyimb@hotmail. selectively modulated PPARc target gene expression. In diabetic KKAy mice, F12016 had insulin-sensitizing com) or Y.X. and glucose-lowering properties, and suppressed weight gain. In vitro, F12016 effectively increased glucose c (xuyanniwendeng@ uptake and blocked cyclin-dependent kinase 5-mediated phosphorylation of PPAR at Ser273, but slightly triggered adipogenesis and less inhibited osteoblastogenesis than rosiglitazone. Moreover, compared with hotmail.com) the full agonist rosiglitazone, F12016 had a distinct group of coregulators and a different predicted binding mode for the PPARc ligand-binding domain. A site mutation assay confirmed the key epitopes, especially Tyr473 in AF-2.
    [Show full text]
  • Dualism of Peroxisome Proliferator-Activated Receptor Α/Γ: a Potent Clincher in Insulin Resistance
    AEGAEUM JOURNAL ISSN NO: 0776-3808 Dualism of Peroxisome Proliferator-Activated Receptor α/γ: A Potent Clincher in Insulin Resistance Mr. Ravikumar R. Thakar1 and Dr. Nilesh J. Patel1* 1Faculty of Pharmacy, Shree S. K. Patel College of Pharmaceutical Education & Research, Ganpat University, Gujarat, India. [email protected] Abstract: Diabetes mellitus is clinical syndrome which is signalised by augmenting level of sugar in blood stream, which produced through lacking of insulin level and defective insulin activity or both. As per worldwide epidemiology data suggested that the numbers of people with T2DM living in developing countries is increasing with 80% of people with T2DM. Peroxisome proliferator-activated receptors are a family of ligand-activated transcription factors; modulate the expression of many genes. PPARs have three isoforms namely PPARα, PPARβ/δ and PPARγ that play a central role in regulating glucose, lipid and cholesterol metabolism where imbalance can lead to obesity, T2DM and CV ailments. It have pathogenic role in diabetes. PPARα is regulates the metabolism of lipids, carbohydrates, and amino acids, activated by ligands such as polyunsaturated fatty acids, and drugs used as Lipid lowering agents. PPAR β/δ could envision as a therapeutic option for the correction of diabetes and a variety of inflammatory conditions. PPARγ is well categorized, an element of the PPARs, also pharmacological effective as an insulin resistance lowering agents, are used as a remedy for insulin resistance integrated with type- 2 diabetes mellitus. There are mechanistic role of PPARα, PPARβ/δ and PPARγ in diabetes mellitus and insulin resistance. From mechanistic way, it revealed that dual PPAR-α/γ agonist play important role in regulating both lipids as well as glycemic levels with essential safety issues.
    [Show full text]
  • Diabetes Mellitus Typ 2 Medikamentöse Therapie
    Übersicht AMT Diabetes mellitus Typ 2 Medikamentöse Therapie L. Cornelius Bollheimer, Christiane Girlich, Ulrike Woenckhaus und Roland Büttner, Regensburg Arzneimitteltherapie 2007;25:175–86. Literatur NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993;16: 621–9. 1. Deutsche Diabetes Gesellschaft. Evidenzbasierte Leitlinie: Epidemiologie 24. Akbar DH. Effect of metformin and sulfonylurea on C-reactive protein und Verlauf des Diabetes mellitus in Deutschland. http://www.deutsche- level in well-controlled type 2 diabetics with metabolic syndrome. En- diabetes-gesellschaft.de/redaktion/mitteilungen/leitlinien/EBL_Update_ docrine 2003;20:215–8. Epidemiologie_05_2004_neues_Layout.pdf. Internetdokument. 2004. 25. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 dia- 2. Seufert J. Kardiovaskuläre Endpunktstudien in der Therapie des Typ-2- betes mellitus. Drugs 2005;65:385–411. Diabetes-mellitus. Dtsch Ärzteblatt 2006;103:A934–42. 26. Parhofer KG, Laubach E, Geiss HC, Otto C. Effect of glucose control on 3. Deutsche Diabetes Gesellschaft. Praxis-Leitlinien der Deutschen Diabe- lipid levels in patients with type 2 diabetes. Dtsch Med Wochenschr tes Gesellschaft. Diabetologie und Stoffwechsel 2006;1:S2. 2002;127:958–62. 4. Häring HU, Matthaei S. Behandlung des Diabetes mellitus Typ 2. Diabe- 27. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin ac- tologie und Stoffwechsel 2006;1:S205–10. tion in obese and lean noninsulin-dependent diabetic subjects. J Clin 5. Brueckel J, Kerner W. Definition, Klassifikation und Diagnostik des Dia- Endocrinol Metab 1991;73:1294–301. betes mellitus. Diabetologie und Stoffwechsel 2006;1:S177–80. 28. Cryer DR, Nicholas SP, Henry DH, Mills DJ, et al. Comparative outcomes 6.
    [Show full text]
  • Comparative Transcriptional Network Modeling of Three PPAR-A/C Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes
    Comparative Transcriptional Network Modeling of Three PPAR-a/c Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes Rene´e Deehan1, Pia Maerz-Weiss2, Natalie L. Catlett1, Guido Steiner2, Ben Wong1, Matthew B. Wright2*, Gil Blander1¤a, Keith O. Elliston1¤b, William Ladd1, Maria Bobadilla2, Jacques Mizrahi2, Carolina Haefliger2, Alan Edgar{2 1 Selventa, Cambridge, Massachusetts, United States of America, 2 F. Hoffmann-La Roche AG, Basel, Switzerland Abstract Aims: To compare the molecular and biologic signatures of a balanced dual peroxisome proliferator-activated receptor (PPAR)-a/c agonist, aleglitazar, with tesaglitazar (a dual PPAR-a/c agonist) or a combination of pioglitazone (Pio; PPAR-c agonist) and fenofibrate (Feno; PPAR-a agonist) in human hepatocytes. Methods and Results: Gene expression microarray profiles were obtained from primary human hepatocytes treated with EC50-aligned low, medium and high concentrations of the three treatments. A systems biology approach, Causal Network Modeling, was used to model the data to infer upstream molecular mechanisms that may explain the observed changes in gene expression. Aleglitazar, tesaglitazar and Pio/Feno each induced unique transcriptional signatures, despite comparable core PPAR signaling. Although all treatments inferred qualitatively similar PPAR-a signaling, aleglitazar was inferred to have greater effects on high- and low-density lipoprotein cholesterol levels than tesaglitazar and Pio/Feno, due to a greater number of gene expression changes in pathways related to high-density and low-density lipoprotein metabolism. Distinct transcriptional and biologic signatures were also inferred for stress responses, which appeared to be less affected by aleglitazar than the comparators. In particular, Pio/Feno was inferred to increase NFE2L2 activity, a key component of the stress response pathway, while aleglitazar had no significant effect.
    [Show full text]
  • Lobeglitazone
    2013 International Conference on Diabetes and Metabolism Lobeglitazone, A Novel PPAR-γ agonist with balanced efficacy and safety Kim, Sin Gon. MD, PhD. Professor, Division of Endocrinology and Metabolism Department of Internal Medicine, Korea University College of Medicine. Disclosure of Financial Relationships This symposium is sponsored by Chong Kun Dang Pharmaceutical Corp. I have received lecture and consultation fees from Chong Kun Dang. Pros & Cons of PPAR-γ agonist Pros Cons • Good glucose lowering • Adverse effects • Durability (ADOPT) (edema, weight gain, • Insulin sensitizing CHF, fracture or rare effects (especially in MS, macular edema etc) NAFLD, PCOS etc) • Possible safety issues • Prevention of new- (risk of MI? – Rosi or onset diabetes (DREAM, bladder cancer? - Pio) ACT-NOW) • LessSo, hypoglycemiathere is a need to develop PPAR-γ • Few GI troubles agonist• Outcome with data balanced efficacy and safety (PROactive) Insulin Sensitizers : Several Issues Rosi, Peak sale ($3.3 billion) DREAM Dr. Nissen Dr. Nissen ADOPT META analysis BARI-2D (5,8) Rosi, lipid profiles RECORD 1994 1997 1999 2000 2002 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Tro out d/t FDA, All diabetes hepatotoxicity drug CV safety Rosi (5) FDA, Black box Rosi, Rosi , CV safety warning - REMS in USA = no evidence - Europe out Pio (7) PIO, bladder cancer CKD 501 Lobeglitazone 2000.6-2004.6 2004.11-2007.1 2007.3-2008.10 2009.11-2011.04 Discovery& Preclinical study Phase I Phase II Phase III Developmental Strategy Efficacy • PPAR activity Discovery & Preclinical study • In vitro & vivo efficacy • Potent efficacy 2000.06 - 2004.06 Phase I 2004.11 - 2007.01 • In vitro screening • Repeated dose toxicity • Metabolites • Geno toxicity • Phase II CYP 450 • Reproductive toxicity 2007.03 - 2008.10 • DDI • Carcinogenic toxicity ADME Phase III Safety 2009.11 - 2011.04 CV Safety / (Bladder) Cancer / Liver Toxicity / Bone loss Lobeglitazone (Duvie) 1.
    [Show full text]
  • Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults with Type 2 Diabetes
    Comparative Effectiveness Review Number 14 Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes This report is based on research conducted by the Johns Hopkins Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0018). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of the Agency for Healthcare Research and Quality or of the U.S. Department of Health and Human Services. This report is intended as a reference and not as a substitute for clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information. This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. Comparative Effectiveness Review Number 14 Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No.
    [Show full text]
  • AVANDIA (Rosiglitazone Maleate Tablets), for Oral Use Ischemic Cardiovascular (CV) Events Relative to Placebo, Not Confirmed in Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------- WARNINGS AND PRECAUTIONS ----------------------- These highlights do not include all the information needed to use • Fluid retention, which may exacerbate or lead to heart failure, may occur. AVANDIA safely and effectively. See full prescribing information for Combination use with insulin and use in congestive heart failure NYHA AVANDIA. Class I and II may increase risk of other cardiovascular effects. (5.1) • Meta-analysis of 52 mostly short-term trials suggested a potential risk of AVANDIA (rosiglitazone maleate tablets), for oral use ischemic cardiovascular (CV) events relative to placebo, not confirmed in Initial U.S. Approval: 1999 a long-term CV outcome trial versus metformin or sulfonylurea. (5.2) • Dose-related edema (5.3) and weight gain (5.4) may occur. WARNING: CONGESTIVE HEART FAILURE • Measure liver enzymes prior to initiation and periodically thereafter. Do See full prescribing information for complete boxed warning. not initiate therapy in patients with increased baseline liver enzyme levels ● Thiazolidinediones, including rosiglitazone, cause or exacerbate (ALT >2.5X upper limit of normal). Discontinue therapy if ALT levels congestive heart failure in some patients (5.1). After initiation of remain >3X the upper limit of normal or if jaundice is observed. (5.5) AVANDIA, and after dose increases, observe patients carefully for signs • Macular edema has been reported. (5.6) and symptoms of heart failure (including excessive, rapid weight gain; • Increased incidence of bone fracture was observed in long-term trials. dyspnea; and/or edema). If these signs and symptoms develop, the heart (5.7) failure should be managed according to current standards of care.
    [Show full text]
  • Synthesis of a Coumarin-Based PPAR Fluorescence Probe for Competitive Binding Assay
    International Journal of Molecular Sciences Article Synthesis of a Coumarin-Based PPARγ Fluorescence Probe for Competitive Binding Assay Chisato Yoshikawa, Hiroaki Ishida , Nami Ohashi and Toshimasa Itoh * Laboratory of Drug Design and Medicinal Chemistry, Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo 194-8543, Japan; [email protected] (C.Y.); [email protected] (H.I.); [email protected] (N.O.) * Correspondence: [email protected] Abstract: Peroxisome proliferator-activated receptor γ (PPARγ) is a molecular target of metabolic syndrome and inflammatory disease. PPARγ is an important nuclear receptor and numerous PPARγ ligands were developed to date; thus, efficient assay methods are important. Here, we investigated the incorporation of 7-diethylamino coumarin into the PPARγ agonist rosiglitazone and used the com- pound in a binding assay for PPARγ. PPARγ-ligand-incorporated 7-methoxycoumarin, 1, showed weak fluorescence intensity in a previous report. We synthesized PPARγ-ligand-incorporating coumarin, 2, in this report, and it enhanced the fluorescence intensity. The PPARγ ligand 2 main- tained the rosiglitazone activity. The obtained partial agonist 6 appeared to act through a novel mechanism. The fluorescence intensity of 2 and 6 increased by binding to the ligand binding domain (LBD) of PPARγ and the affinity of reported PPARγ ligands were evaluated using the probe. Keywords: PPARγ ligand; coumarin; fluorescent ligand; screening; crystal structure Citation: Yoshikawa, C.; Ishida, H.; Ohashi, N.; Itoh, T. Synthesis of a Coumarin-Based PPARγ 1. Introduction Fluorescence Probe for Competitive Binding Assay. Int. J. Mol. Sci. 2021, Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear receptor su- 22, 4034.
    [Show full text]
  • The Effect of Rosiglitazone on Overweight Subjects with Type 1 Diabetes
    Clinical Care/Education/Nutrition ORIGINAL ARTICLE The Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes SUZANNE M. STROWIG, MSN, RN the potentially serious consequences of PHILIP RASKIN, MD excessive weight gain and insulin- induced hypoglycemia, investigators con- tinue to search for treatments that address both the treatment of insulin deficiency as well as other metabolic abnormalities that OBJECTIVE — To evaluate the safety and effectiveness of rosiglitazone in the treatment of are associated with diabetes (5). overweight subjects with type 1 diabetes. Insulin resistance, a metabolic abnor- mality common in type 2 diabetes, ap- RESEARCH DESIGN AND METHODS — A total of 50 adult type 1 diabetic subjects 2 pears to be present in individuals with with a baseline BMI Ն27 kg/m were randomly assigned in a double-blind fashion to take insulin and placebo (n ϭ 25) or insulin and rosiglitazone 4 mg twice daily (n ϭ 25) for a period of 8 type 1 diabetes, as well. Although insulin months. Insulin regimen and dosage were modified in all subjects to achieve near-normal resistance in type 2 diabetes is generally glycemic control. associated with obesity, hypertension, dyslipidemia, and other metabolic disor- RESULTS — Both groups experienced a significant reduction in HbA1c (A1C) level (rosigli- ders, studies have shown that overweight tazone: 7.9 Ϯ 1.3 to 6.9 Ϯ 0.7%, P Ͻ 0.0001; placebo: 7.7 Ϯ 0.8 to 7.0 Ϯ 0.9%, P ϭ 0.002) and as well as normal-weight adults with type a significant increase in weight (rosiglitazone: 97.2 Ϯ 11.8 to 100.6 Ϯ 16.0 kg, P ϭ 0.008; 1 diabetes can have peripheral and he- Ϯ Ϯ ϭ ϭ placebo: 96.4 12.2 to 99.1 15.0, P 0.016).
    [Show full text]